HBM Healthcare Investments AG Share Price

Equities

HBMN

CH0012627250

Investment Management & Fund Operators

Market Closed - Swiss Exchange 16:31:30 26/04/2024 BST 5-day change 1st Jan Change
188 CHF 0.00% Intraday chart for HBM Healthcare Investments AG 0.00% +2.96%

Financials

Sales 2024 * -42.4M -46.36M -3.71B Sales 2025 * 46.1M 50.41M 4.04B Capitalization 1.3B 1.42B 114B
Net income 2024 * -71M -77.63M -6.22B Net income 2025 * 18M 19.68M 1.58B EV / Sales 2024 * -29.9 x
Net cash position 2024 * 32M 34.99M 2.8B Net cash position 2025 * 53M 57.95M 4.64B EV / Sales 2025 * 27 x
P/E ratio 2024 *
-18.2 x
P/E ratio 2025 *
77.7 x
Employees 700
Yield 2024 *
3.99%
Yield 2025 *
2.99%
Free-Float 82.11%
More Fundamentals * Assessed data
Dynamic Chart
Current month-2.89%
1 month-1.05%
3 months+4.79%
6 months+26.86%
Current year+2.96%
More quotes
1 week
182.20
Extreme 182.2
191.40
1 month
180.60
Extreme 180.6
196.00
Current year
155.00
Extreme 155
196.00
1 year
135.20
Extreme 135.2
210.00
3 years
135.20
Extreme 135.2
367.00
5 years
135.20
Extreme 135.2
367.00
10 years
71.85
Extreme 71.85
367.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 30/06/01
Director of Finance/CFO 53 31/10/11
Corporate Secretary 60 -
Members of the board TitleAgeSince
Chairman 68 31/05/09
Director/Board Member 69 17/06/21
Director/Board Member 52 31/12/11
More insiders
Date Price Change Volume
26/04/24 188 0.00% 2,173
25/04/24 188 -0.42% 4,797
24/04/24 188.8 +1.29% 876
23/04/24 186.4 +0.43% 3,723
22/04/24 185.6 -1.28% 5,992

Delayed Quote Swiss Exchange, April 26, 2024 at 04:31 pm

More quotes
HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. As a holding company, it is involved in the acquisition, disposal and management of a diversified portfolio, as well as in financing and supporting the portfolio firms as a key partner. It focuses on companies with products either at an advanced stage of development or already available on the market. The primary investment areas are Western Europe and the United States. The Company's portfolio includes approximately 25 companies. As of March 31, 2012, the Company had six wholly owned subsidiaries, including three subsidiaries on Cayman Islands, two Barbados-based subsidiaries and a subsidiary in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
188 CHF
Average target price
236 CHF
Spread / Average Target
+25.53%
Consensus

Annual profits - Rate of surprise